Systematic Evolution Of Ligands By Exponential Enrichment: Tissue Selex

Kirk Jensen

Systematic Evolution Of Ligands By Exponential Enrichment: Tissue Selex

Kirk Jensen (Inventor)

Nutrition, Diabetes And Gut Health

Research output: Patent

20 Downloads (Pure)

Abstract

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells
ghosts, glioblastomas, and lymphomas are described.

Original language	English
Patent number	AU 732961 B2
IPC	AU 732961 B2
Publication status	Published or Issued - 3 May 2001

Access to Document

AU_732961_B2Final published version, 4.58 MBLicence: Unspecified

Cite this

@misc{25300ae66d89435f9f55ba7f78e24a5a,

title = "Systematic Evolution Of Ligands By Exponential Enrichment: Tissue Selex",

abstract = "This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cellsghosts, glioblastomas, and lymphomas are described.",

author = "Kirk Jensen",

year = "2001",

month = may,

day = "3",

language = "English",

publisher = "Australian Patent Office",

type = "Patent",

note = "AU 732961 B2; AU 732961 B2",

}

TY - PAT

T1 - Systematic Evolution Of Ligands By Exponential Enrichment: Tissue Selex

AU - Jensen, Kirk

PY - 2001/5/3

Y1 - 2001/5/3

N2 - This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cellsghosts, glioblastomas, and lymphomas are described.

AB - This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cellsghosts, glioblastomas, and lymphomas are described.

M3 - Patent

M1 - AU 732961 B2

PB - Australian Patent Office

ER -